Cite
Wagle MC, Kirouac D, Klijn C, et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol. 2018;2(1):7doi: 10.1038/s41698-018-0051-4.
Wagle, M. C., Kirouac, D., Klijn, C., Liu, B., Mahajan, S., Junttila, M., Moffat, J., Merchant, M., Huw, L., Wongchenko, M., Okrah, K., Srinivasan, S., Mounir, Z., Sumiyoshi, T., Haverty, P. M., Yauch, R. L., Yan, Y., Kabbarah, O., Hampton, G., Amler, L., Ramanujan, S., Lackner, M. R., & Huang, S. A. (2018). A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ precision oncology, 2(1), 7. https://doi.org/10.1038/s41698-018-0051-4
Wagle, Marie-Claire, et al. "A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types." NPJ precision oncology vol. 2,1 (2018): 7. doi: https://doi.org/10.1038/s41698-018-0051-4
Wagle MC, Kirouac D, Klijn C, Liu B, Mahajan S, Junttila M, Moffat J, Merchant M, Huw L, Wongchenko M, Okrah K, Srinivasan S, Mounir Z, Sumiyoshi T, Haverty PM, Yauch RL, Yan Y, Kabbarah O, Hampton G, Amler L, Ramanujan S, Lackner MR, Huang SA. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol. 2018 Mar 07;2(1):7. doi: 10.1038/s41698-018-0051-4. eCollection 2018. PMID: 29872725; PMCID: PMC5871852.
Copy
Download .nbib